Inspira Collaborates With New York's Westchester Medical Center to Evaluate the INSPIRA ART100 Functionality and Performance in Clinical Scenarios
Inspira Collaborates With New York's Westchester Medical Center to Evaluate the INSPIRA ART100 Functionality and Performance in Clinical Scenarios
RA'ANANA, Israel, Dec. 4, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN), (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, entered into a strategic collaboration with Westchester Medical Center in Valhalla, New York. Westchester Medical Center, the flagship hospital in the Westchester Medical Center Health Network, will evaluate the performance and effectiveness of the new U.S. Food and Drug Administration (FDA) cleared INSPIRA ART100 systems in various real-world clinical scenarios, exposing Inspira's products and technologies to leading physicians and medical institutions.
以色列拉阿那納,2024年12月4日/PRNewswire/ -- Inspira Technologies OXY b.H.N. Ltd.(納斯達克:IINN),(納斯達克:IINNW)("Inspira Technologies","Inspira"或"公司"),是一家開創性的生命支持科技公司,與紐約瓦爾哈拉的韋斯特切斯特醫療中心建立了戰略合作關係。韋斯特切斯特醫療中心是韋斯特切斯特醫療中心衛生網絡的旗艦醫院,將在各種真實臨床場景中評估新的美國食品和藥物管理局(FDA)批准的INSPIRA ART100系統的性能和有效性,使Inspira的產品和技術能夠接觸到領先的醫生和醫療機構。
The strategic collaboration allows for Westchester Medical Center, a premier provider of advanced medical care, and Inspira Technologies, a pioneer of breakthrough technologies, to advance critical patient care with the deployment of Inspira's proprietary INSPIRA ART100 systems. The parties have entered the strategic collaboration with the intention to mutually explore a long-term collaboration towards the future deployment of Inspira's next-generation flagship technology, its INSPIRA ART system, which is currently in development and which is being designed to treat acute respiratory failure by elevating declining oxygen saturation levels in minutes without mechanical ventilators.
這一戰略合作關係使韋斯特切斯特醫療中心,這家先進醫療保健的主要提供者,和Inspira Technologies,這家突破性科技的先鋒,能夠通過部署Inspira的專有INSPIRA ART100系統來提升關鍵的患者護理。雙方以共同探索未來部署Inspira下一代旗艦科技INSPIRA ARt系統的長期合作關係爲目標,該系統目前正在開發中,旨在在不使用機械通氣器的情況下,在幾分鐘內提升下降的氧飽和度水平,以治療急性呼吸衰竭。
"We are thrilled to supply Westchester Medical Center with our FDA-cleared INSPIRA ART100 systems," Joe Hayon, co-founder and President of Inspira Technologies. "We believe that this collaboration validates the growing interest in our innovative technology and also provides us with an opportunity to demonstrate its capabilities in one of New York's premier medical networks."
「我們很高興向韋斯特切斯特醫療中心提供我們的FDA批准的INSPIRA ART100系統,」Inspira Technologies的聯合創始人兼總裁Joe Hayon表示。「我們相信,這次合作驗證了人們對我們創新科技不斷增長的興趣,同時也爲我們提供了一個機會,在紐約的主要醫療網絡中展示其能力。」
David Spielvogel, MD, Section Chief of Cardiothoracic Surgery, Westchester Medical Center, said: "This partnership exemplifies Westchester Medical Center's commitment to investing in innovative technologies to provide the highest, safest, and most effective care. By integrating this technology we aim to enhance our treatment of acute respiratory failure and improve patient outcomes. As one of the few centers in New York State performing Cardiopulmonary Bypass (CPB) and Extracorporeal Membrane Oxygenation (ECMO), we are uniquely positioned to leverage this advanced technology for the benefit of our patients."
韋斯特切斯特醫療中心心胸外科主任David Spielvogel醫生表示:「這項合作關係體現了韋斯特切斯特醫療中心對投資於創新科技的承諾,以提供最高、最安全、最有效的護理。通過整合這項科技,我們旨在增強急性呼吸衰竭的治療並改善患者結果。作爲紐約州少數幾家執行體外循環(CPB)和體外膜氧合(ECMO)治療的中心之一,我們在利用這項先進科技爲患者帶來好處方面具有獨特優勢。」
About Westchester Medical Center Health Network
關於韋奇斯特醫療中心醫療網絡
The Westchester Medical Center Health Network (WMCHealth) is a 1,700-bed healthcare system headquartered in Valhalla, New York, with nine hospitals on seven campuses spanning 6,200 square miles of the Hudson Valley. WMCHealth employs more than 12,000 people and has nearly 3,000 attending physicians. The Network has Level I (adult and pediatric), Level II and Level III trauma centers, the region's only acute care children's hospital, an academic medical center, several community hospitals, dozens of specialized institutes and centers, Comprehensive and Primary Stroke Centers, skilled nursing facilities, home-care services and one of the largest mental health systems in New York State. Today, WMCHealth is the pre-eminent provider of integrated health care in the Hudson Valley. For more information about WMCHealth, visit WMCHealth.org or follow WMCHealth on Facebook, Instagram, LinkedIn, YouTube, and X.
韋奇斯特醫療中心醫療網絡(WMCHealth)是一家總部位於紐約州瓦爾哈拉的1,700牀醫療保健系統,擁有九家醫院分佈在七個校園,覆蓋6,200平方英里的哈德遜谷。WMCHealth僱傭了超過12,000名員工,擁有近3,000名主治醫生。該網絡設有一級(成人和兒科)、二級和三級創傷中心,地區唯一的急性護理兒童醫院,一個學術醫療中心,若干社區醫院,數十個專業機構和中心,綜合性和初級中風中心,熟練護理設施,家庭護理服務,以及紐約州最大的心理健康系統之一。今天,WMCHealth是哈德遜谷地區主要的綜合醫療保健提供者。如需了解更多關於WMCHealth的信息,請訪問WMCHealth.org,或在Facebook、Instagram、LinkedIn、YouTube和X上關注WMCHealth。
About Inspira Technologies OXY B.H.N. Ltd.
關於Inspira Technologies OXY b.H.N.有限公司
Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilators, with patient being awake during treatment. The INSPIRA ART is being equipped with clip-on HYLA blood sensor, a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patient's condition without the need for intermittent actual blood samples, and potentially supporting physicians in making informed decisions.
Inspira Technologies是生命支持和呼吸治療領域的創新醫療科技公司。該公司開發了一項突破性的增強呼吸技術(INSPIRA ART),這是一款具有革命性的設備,即將徹底改變190億美元的機械通風市場。每年有2000萬重症監護病房患者患急性呼吸衰竭,其中許多依賴於呼吸機,INSPIRA ARt提供了一個潛在的替代方案,通過在幾分鐘內提高和穩定下降的血氧飽和度,使患者在治療過程中保持清醒,而無需使用呼吸機。INSPIRA ARt將配備clip-on HYLA血液傳感器,一種實時連續血液監測技術,旨在在無需間歇實際血樣的情況下警示醫生患者病情變化,可能支持醫生做出明智的決策。
The Company's INSPIRA ART100 system has obtained FDA 510(k) clearance for use in Cardiopulmonary Bypass procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.
該公司的INSPIRA ART100系統已經獲得FDA 510(k)認證,可以用於心肺旁路手術,同時還取得了以色列AMAR認證,可用於體外膜肺氧合和心肺旁路手術。
The Company's other products and technologies, including the INSPIRA ART also known as the INSPIRA ART500 or Gen 2, the INSPIRA Cardi-ART portable modular device, VORTX orbiting Oxygen Delivery System and HYLA blood sensor, are currently being designed and developed, and have not yet been tested or used in humans and have not been approved by any regulatory entity.
公司的其他產品和技術,包括名爲INSPIRA ARt的也被稱爲INSPIRA ART500或Gen 2的產品、INSPIRA Cardi-ARt便攜式模塊化設備、VORTX軌道式氧氣傳送系統和HYLA血液傳感器,目前正在設計和開發中,並未經過人體測試或使用,也未獲得任何監管機構的批准。
For more information, please visit our corporate website:
有關更多信息,請訪問我們的公司網站:
Forward-Looking Statement Disclaimer
前瞻性聲明免責聲明
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of the collaboration to enable the advancement of critical patient care, the prospective long-term collaboration in deploying the INSPIRA ART System, the belief that this collaboration validates the growing interest in the Company's innovative technology and provides the Company with an opportunity to demonstrate its capabilities in one of New York's premier medical networks, the belief that this collaboration exemplifies Westchester Medical Center's commitment to investing in innovative technologies, that Westchester Medical Center aims to enhance its treatment of acute respiratory failure and improve patient outcomes through the integration of this technology and the belief that Westchester Medical Center is uniquely positioned to leverage this advanced technology for the benefit of its patients. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, www.sec.gov.
本新聞稿包含根據美國聯邦證券法規定的明確或暗含的前瞻性聲明。這些前瞻性聲明及其含義僅基於公司管理層當前的期望,並受多個因素和不確定性的影響,這些因素和不確定性可能導致實際結果與前瞻性聲明中描述的結果有重大差異。例如,公司在討論合作潛力以推動關鍵患者護理的進展、部署INSPIRA ARt系統的長期合作前景時,使用了前瞻性聲明,認爲該合作驗證了人們對公司創新科技日益增長的興趣,併爲公司提供了在紐約頂級醫療網絡中展示其能力的機會,認爲該合作體現了西切斯特醫療中心對投資創新科技的承諾,西切斯特醫療中心旨在通過整合該技術來增強急性呼吸衰竭的治療和改善患者的治療結果,並認爲西切斯特醫療中心在利用這種先進技術爲其患者帶來益處方面具備獨特的優勢。這些前瞻性聲明及其含義僅基於公司管理層當前的期望,並受多個因素和不確定性的影響,這些因素和不確定性可能導致實際結果與前瞻性聲明中描述的結果有重大差異。除法律另有規定外,公司並沒有公開發布任何修改這些前瞻性聲明的義務,以反映本聲明日期後發生的事件或情況,或反映意外事件的發生。關於影響公司的風險和不確定性的更詳細信息,請參閱公司於2023年12月31日結束的財年的20-F表格年度報告中的「風險因素」一節,該報告已向美國證券交易委員會(SEC)提交,並可在SEC網站www.sec.gov上獲取。
Contact:
聯繫方式:
Inspira Technologies – Media Relations
Email: [email protected]
Phone: +972-9-9664485
Inspira Technologies - 媒體關係
電子郵件: [email protected]
電話:+972-9-9664485
Copyright 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.
版權所有 © 2018-2024 Inspira Technologies OXY B.H.N. LTD.。保留所有權利。
Logo:
徽標:
SOURCE Inspira Technologies
來源:Inspira Technologies
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?
譯文內容由第三人軟體翻譯。